Technologies

This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).

The proposing team that works at CNR ISTEC has recently patented a technology for the production of the Smart Polycrystals (SP), i.e. transparent YAG-based ceramic polycrystals (Y₃Al₅O₁₂) variably doped with rare earths ions and transition metals ions. The SPs solve the problem of the reduction of the efficiency in the solid state laser systems caused by the inhomogeneous heating of the single crystals during the emission process.

Polymer development is approaching to a new stage of advancement in which new functionalities especially in combination with conductive polymers and nanomaterials are more effective. In this context the study of new composites is the key to enable the development of disruptive technologies as additive manufacturing. Increasing electrical conductivity open the way to a new class of objects to be prototyped rapidly at low cost with a high level of customization.

We present a new concept of ultra-compact, configurable and implantable brain computer interface (BCI). The device can be applied to monitor or stimulate, with high temporal and spatial accuracy, neural activity of the brain. It allows implementation of closed-loop algorithms in real time applications. The system can be also used in vitro to monitor or induce cell growth or as tDCS tool. The system can be customized (microelectrodes materials and shapes) to guarantee the best solution for the specific application.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.